FR2899588B1 - Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee - Google Patents

Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee

Info

Publication number
FR2899588B1
FR2899588B1 FR0651273A FR0651273A FR2899588B1 FR 2899588 B1 FR2899588 B1 FR 2899588B1 FR 0651273 A FR0651273 A FR 0651273A FR 0651273 A FR0651273 A FR 0651273A FR 2899588 B1 FR2899588 B1 FR 2899588B1
Authority
FR
France
Prior art keywords
galactose
activator
regulator
derived
glycoside compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0651273A
Other languages
English (en)
Other versions
FR2899588A1 (fr
Inventor
Nathalie Pineau
Maria Dalko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0651273A priority Critical patent/FR2899588B1/fr
Application filed by LOreal SA filed Critical LOreal SA
Priority to PCT/EP2007/053360 priority patent/WO2007116013A1/fr
Priority to EP07727828.1A priority patent/EP2007746B1/fr
Priority to US12/296,310 priority patent/US20090305997A1/en
Priority to ES07727828.1T priority patent/ES2605026T3/es
Priority to CN201610168876.6A priority patent/CN105748312A/zh
Priority to CNA2007800122134A priority patent/CN101415699A/zh
Publication of FR2899588A1 publication Critical patent/FR2899588A1/fr
Application granted granted Critical
Publication of FR2899588B1 publication Critical patent/FR2899588B1/fr
Priority to US14/183,205 priority patent/US20140220081A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
FR0651273A 2006-04-07 2006-04-07 Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee Active FR2899588B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0651273A FR2899588B1 (fr) 2006-04-07 2006-04-07 Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee
EP07727828.1A EP2007746B1 (fr) 2006-04-07 2007-04-05 Utilisation d'un composé c-glycoside dérivé du galactose en tant qu'agent pour activer et réguler l'immunité cutanée
US12/296,310 US20090305997A1 (en) 2006-04-07 2007-04-05 Use of a galactose-derived c-glycoside compound as an agent for activating and regulating cutaneous immunity
ES07727828.1T ES2605026T3 (es) 2006-04-07 2007-04-05 Uso de un compuesto de C-glicósido derivado de galactosa como agente para activar y regular la inmunidad cutánea
PCT/EP2007/053360 WO2007116013A1 (fr) 2006-04-07 2007-04-05 Utilisation d'un composé c-glycoside dérivé du galactose en tant qu'agent pour activer et réguler l'immunité cutanée
CN201610168876.6A CN105748312A (zh) 2006-04-07 2007-04-05 半乳糖衍生的c-糖苷化合物及其组合物和应用
CNA2007800122134A CN101415699A (zh) 2006-04-07 2007-04-05 半乳糖衍生的c-糖苷化合物作为用于活化和调节皮肤免疫性的试剂的应用
US14/183,205 US20140220081A1 (en) 2006-04-07 2014-02-18 Use of a galactose-derived c-glycoside compound as an agent for activating and regulating cutaneous immunity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0651273A FR2899588B1 (fr) 2006-04-07 2006-04-07 Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee

Publications (2)

Publication Number Publication Date
FR2899588A1 FR2899588A1 (fr) 2007-10-12
FR2899588B1 true FR2899588B1 (fr) 2009-02-27

Family

ID=37487596

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0651273A Active FR2899588B1 (fr) 2006-04-07 2006-04-07 Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee

Country Status (6)

Country Link
US (2) US20090305997A1 (fr)
EP (1) EP2007746B1 (fr)
CN (2) CN105748312A (fr)
ES (1) ES2605026T3 (fr)
FR (1) FR2899588B1 (fr)
WO (1) WO2007116013A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2939677B1 (fr) * 2008-12-16 2011-06-10 Oreal Utilisation de derives c-glycosides comme agents anti-adhesion microbienne
FR2951377B1 (fr) * 2009-10-21 2012-06-22 Oreal Association d'un lysat de probiotique et d'un derive c-glycoside
FR2961511A1 (fr) * 2010-06-16 2011-12-23 Oreal C-glycosides aromatiques antioxydants cosmetiques
JP2014505058A (ja) * 2011-01-11 2014-02-27 ザ・ユニバーシティ・オブ・テキサス・エム・ディー・アンダーソン・キャンサー 増殖性および炎症性皮膚疾患の治療用単糖ベース化合物
JP6545660B2 (ja) 2013-04-05 2019-07-17 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗増殖活性を有する２−デオキシ−単糖類のエステル
KR102282246B1 (ko) * 2020-10-27 2021-07-27 쿼럼바이오 주식회사 갈락토스를 함유하는 아토피 피부염의 예방, 개선, 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6424561B1 (en) * 2000-07-18 2002-07-23 Micron Technology, Inc. MRAM architecture using offset bits for increased write selectivity
DE10138935B4 (de) * 2000-08-11 2007-08-02 Kotobuki Pharmaceutical Co., Ltd, , Hanishina Synthetische Verbindungen vom Nicht-Mucintyp oder ihre mit einem Träger konjugierten Verbindungen, unter deren Verwendung hergestellte monoclonale Antikörper, diese umfassende Antitumormittel Immunstimulantien und Mittel gegen das humane Immundefizienzvirus
FR2818646B1 (fr) * 2000-12-22 2006-06-23 Oreal Nouveaux derives c-glycoside et utilisation
FR2818547B1 (fr) * 2000-12-22 2006-11-17 Oreal Nouveaux derives c-glycosides et utilisation
WO2004094445A1 (fr) * 2003-04-18 2004-11-04 Iowa State University Research Foundation, Inc Analogue de l'isopropylthio-galactoside plus stable pour induction de l'expression proteique

Also Published As

Publication number Publication date
CN105748312A (zh) 2016-07-13
EP2007746A1 (fr) 2008-12-31
FR2899588A1 (fr) 2007-10-12
WO2007116013A1 (fr) 2007-10-18
ES2605026T3 (es) 2017-03-10
US20090305997A1 (en) 2009-12-10
US20140220081A1 (en) 2014-08-07
CN101415699A (zh) 2009-04-22
EP2007746B1 (fr) 2016-08-31

Similar Documents

Publication Publication Date Title
FR2899588B1 (fr) Utilisation de compose c-glycoside derive de galactose comme agent activateur et regulateur de l'immunite cutanee
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
EP1736160A4 (fr) Oligosaccharides d'algine et derives de ceux-ci ainsi que leur fabrication et leur utilisation
FR2958542B1 (fr) Utilisation cosmetique de l'oridonine comme agent amincissant
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
WO2008018045A3 (fr) composition de soins personnels
EP1928398A4 (fr) Composition cosmetique contenant des microspheres thermoplastiques et des agents benefiques pour la peau
WO2009085889A3 (fr) Compositions et procédés pour réduire ou empêcher la perte d'eau par la peau
BRPI0719497A2 (pt) "composição, processo de preparação de uma composição, usos de uma composição e uso coméstico de uma composição"
WO2009022077A3 (fr) Utilisation d'hespéridine ou de l'un de ses dérivés pour la prévention et/ou le traitement des peaux relâchées
FR2929509B1 (fr) L'utilisation de glycosides d'alkyle ou de melanges de glycosides d'alkyle en tant qu'agents destines a inhiber la croissance microbienne, et compositions contenant lesdits glycosides d'alkyle.
ATE548019T1 (de) Hautaufhellende mittel, zusammensetzungen und verfahren
WO2008069910A3 (fr) Lotion hydratante auto-chauffante contenue dans un flacon à double compartiment
FR2899464B1 (fr) Compose c-glycoside et utilisation comme agent activateur et regulateur de l'immunite cutanee
FR2899468B1 (fr) Utilisation de c-glycosides derives de galactose comme agent protecteur et/ou activateur des lumphocytes gamma delta t
FR2899466B1 (fr) Utilisation de compose c-glycoside agent activateur et regulateur de l'immunite cutanee
FR2899469B1 (fr) Utilisation de derive de d- et l-fucose comme agent protecteur et/ou activateur des lymphocytes gamma delta t
FR2899474B1 (fr) Utilisation de compose c-glycoside derive d- et l-fucose comme agent activateur et regulateur de l'imminite cutanee
FR2899587B1 (fr) Utilisation de compose c-glycoside derive de lactose comme agent activateur et regulateur de l'immunite cutanee
WO2010130776A3 (fr) Utilisation de delta-tocophéryl-carbohydrate en tant qu'agent de dépigmentation
FR2899463B1 (fr) Utilisation dej compose c-glycoside comme agent activateur et regulateur de l'immunite cutanee
HUP0401422A2 (en) Use of l-arginine as vasoaktive ingredient absorbing through skin for external application
FR2903009B1 (fr) Composition cosmetique et/ou dermatologique associant un derive de c-glycoside et un agent desquamant
FR2896691B1 (fr) Utilisation d'esters d'alkylglucoside comme inducteurs de beta-defensines
FR2929510B1 (fr) Utilisation d'au moins un glycoside d'alkyle en tant qu'agen qu'agent anti-vieillissement et/ou calmant des peaux sensibles dans des compositions cosmetiques, et methodes de soin cosmetique utilisant les dites compositions.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18